Related Experiment Video
Updated: Jul 19, 2025
11:34
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
2.3K
Challenge Inoculum for Hepatitis C Virus Controlled Human Infection Model.
T Jake Liang1, John L M Law2, Thomas Pietschmann3
1Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Summary
Developing a safe and effective hepatitis C virus (HCV) challenge inoculum is crucial for controlled human infection models (CHIM). Human-derived, well-characterized viral inocula are proposed as the most appropriate approach for vaccine development.
Area of Science:
- Virology
- Immunology
- Infectious Diseases
Background:
- Controlled human infection models (CHIM) require safe and standardized challenge inocula.
- Hepatitis C virus (HCV) research necessitates specific inoculum properties for accurate study outcomes.
Purpose of the Study:
- To propose an optimal approach for developing challenge inocula for HCV CHIM.
- To outline the necessary characteristics and testing phases for these inocula.
Main Methods:
- Characterization of human-derived, high-titer HCV inocula across multiple genotypes.
- Step-wise testing of inocula in human volunteers to assess safety, reproducibility, and curability.
Main Results:
- Human-derived inocula with extensive virologic, serologic, and molecular data are identified as most appropriate.
- Pre-clinical safety, reproducibility, and curability assessments are essential before efficacy trials.
Conclusions:
- Well-characterized, human-derived HCV inocula are recommended for CHIM.
- Rigorous volunteer testing ensures the safety and reliability of inocula for vaccine efficacy studies.
